Martin Cerda, DO
Cardiovascular Disease · Scottsdale, AZNPI 1952644312
Payments from drug & device makers
What this record shows
This record is dominated by grants: $53,961 of the $66,161 with a category attached, or 81.6%. 29 manufacturers reported payments, led by Medtronic at 53.2% of the total. Reporting peaked in 2020 at $32,586 and has fallen 93.7% since, to $2,041 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $255.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$35K
- Boston Scientific$14K
- Abbott$10K
- Biotronik Inc.$2K
- E.r. Squibb & Sons, L.L.C.$796
- Novartis$550
- plus $3K from 23 others
What the payments were for
- Grants$53,96182%
- Travel & lodging$3,3645%
- Food & beverage$8,29213%
- Education$5451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 45 | $35,196 |
| Boston Scientific | 13 | $13,508 |
| Abbott | 8 | $10,229 |
| Biotronik Inc. | 24 | $2,484 |
| E.r. Squibb & Sons, L.L.C. | 22 | $796 |
| Novartis | 28 | $550 |
| Amgen | 24 | $485 |
| Edwards Lifesciences | 2 | $375 |
| Novo Nordisk | 9 | $281 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $279 |
| AstraZeneca | 9 | $269 |
| Pfizer | 12 | $214 |
| Actelion Pharmaceuticals US, Inc. | 6 | $174 |
| Recor Medical Inc | 1 | $141 |
| Elutia, Inc. | 1 | $141 |
| Heartflow, Inc. | 2 | $138 |
| Johnson & Johnson | 7 | $131 |
| Boehringer Ingelheim | 5 | $125 |
| Alnylam Pharmaceuticals Inc. | 6 | $119 |
| Esperion Therapeutics, Inc. | 1 | $112 |
| Merck | 5 | $90 |
| Cardiva Medical, Inc. | 1 | $66 |
| Bayer | 3 | $61 |
| Philips North America LLC | 3 | $57 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $48 |
| Lilly USA, LLC | 2 | $29 |
| Siemens Medical Solutions USA, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM$7,500
- GENERAL BRADY$5,000
- Edora$1,495
- Acticor$1,495
- Rivacor$1,495
- Arctic Front$1,213
- BioMonitor$748
- Solia$748
- Sentus$747
- Plexa$747
- WATCHMAN Access System$631
- CAMZYOS$479
- Adapta$265
- Repatha$253
- Edwards SAPIEN 3 Transcatheter Heart Valve$232
- EnSite Precision Cardiac Mapping System$207
- HeartMate 3 Left Ventricular Dev$180
- MERLIN@HOME$167
- MitraClip$148
- Micra$144
How this compares
$66,161 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 291 | $316,692 |
| EntrestoSacubitril/Valsartan | 98 | $128,570 |
| JardianceEmpagliflozin | 79 | $117,704 |
| FarxigaDapagliflozin Propanediol | 56 | $54,542 |
| XareltoRivaroxaban | 24 | $29,288 |
| Repatha SureclickEvolocumab | 14 | $10,928 |
| Metoprolol Succinate | 255 | $4,082 |
| Flecainide Acetate | 58 | $2,954 |
| Losartan Potassium | 307 | $2,647 |
| Atorvastatin Calcium | 160 | $2,279 |
| Clonidine | 16 | $2,172 |
| Rosuvastatin Calcium | 177 | $2,085 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 71 | $1,779 |
| Bumetanide | 35 | $1,312 |
| Valsartan | 32 | $1,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $214 | $316,692291 claims |
| NovartisEntresto | $550 | $128,57098 claims |
| Boehringer IngelheimJardiance | $125 | $117,70479 claims |
| AstraZenecaFarxiga | $269 | $54,54256 claims |
| Johnson & JohnsonXarelto | $131 | $29,28824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Scottsdale
- Krishnaswami VijayaraghavanScottsdale$927K
- Paul UnderwoodScottsdale$259K
- Robert BurkeScottsdale$207K
- David RizikScottsdale$128K
- Pattara RattanawongScottsdale$43K
- Mayank SardanaScottsdale$36K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Steven MottlTucson$340K
- Omar WaniFlagstaff$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.